A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous...

Por Baker, Valerie L., Jones, Christopher A., Doody, Kevin, Foulk, Russell, Yee, Bill, Adamson, G. David, Cometti, Barbara, DeVane, Gary, Hubert, Gary, Trevisan, Silvia, Hoehler, Fred, Jones, Clarence, Soules, Michael
Publicado em 2014

NorLeu(3)-A(1–7) Stimulation of Diabetic Foot Ulcer Healing: Results of a Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

Por Balingit, Peter P., Armstrong, David G., Reyzelman, Alexander M., Bolton, Laura, Verco, Shelagh J., Rodgers, Kathleen E., Nigh, Katherine A., diZerega, Gere S.
Publicado no Wound Repair Regen (2012)

Safety and Efficacy of High-Dose Tamoxifen and Sulindac for Desmoid Tumor in Children: Results of a Children’s Oncology Group (COG) Phase II Study

Por Skapek, Stephen X., Anderson, James R., Hill, D. Ashley, Henry, David, Spunt, Sheri L., Meyer, William, Kao, Simon, Hoffer, Fredric A., Grier, Holcombe E., Hawkins, Douglas S., Raney, R. Beverly
Publicado no Pediatr Blood Cancer (2012)

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Por Spiera, Robert F, Gordon, Jessica K, Mersten, Jamie N, Magro, Cynthia M, Mehta, Mansi, Wildman, Horatio F, Kloiber, Stacey, Kirou, Kyriakos A, Lyman, Stephen, Crow, Mary K
Publicado em 2011

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem...

Por Mims, Alice S., Mishra, Anjali, Orwick, Shelley, Blachly, James, Klisovic, Rebecca B., Garzon, Ramiro, Walker, Alison R., Devine, Steven M., Walsh, Katherine J., Vasu, Sumithira, Whitman, Susan, Marcucci, Guido, Jones, Daniel, Heerema, Nyla A., Lozanski, Gerard, Caligiuri, Michael A., Bloomfield, Clara D., Byrd, John C., Piekarz, Richard, Grever, Michael R., Blum, William
Publicado no Haematologica (2018)

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Por Kirschbaum, Mark, Frankel, Paul, Popplewell, Leslie, Zain, Jasmine, Delioukina, Maria, Pullarkat, Vinod, Matsuoka, Deron, Pulone, Bernadette, Rotter, Arnold J., Espinoza-Delgado, Igor, Nademanee, Auayporn, Forman, Stephen J., Gandara, David, Newman, Edward
Publicado em 2011

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

Por Bondarenko, Igor M, Ingrosso, Antonella, Bycott, Paul, Kim, Sinil, Cebotaru, Cristina L
Publicado no BMC Cancer (2015)

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

Por Martin-Castillo, Begoña, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A., Amillano, Kepa, Domínguez, Severina, Luque, Maria, Stradella, Agostina, Morilla, Idoia, Viñas, Gemma, Cortés, Javier, Cuyàs, Elisabet, Verdura, Sara, Fernández-Ochoa, Álvaro, Fernández-Arroyo, Salvador, Segura-Carretero, Antonio, Joven, Jorge, Pérez, Elsa, Bosch, Neus, Garcia, Margarita, López-Bonet, Eugeni, Saidani, Samiha, Buxó, Maria, Menendez, Javier A.
Publicado no Oncotarget (2018)

Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study

Por Braeckman, Johan, Michielsen, Dirk
Publicado em 2014

Treatment of Myelodysplastic Syndrome with Two Schedules and Doses of Oral Topotecan: A Randomized...

Por Grinblatt, David L., Yu, Daohai, Hars, Vera, Vardiman, James W., Powell, Bayard L., Nattam, Sreenivasa, Silverman, Lewis R., de Castro, Carlos, Stone, Richard M., Bloomfield, Clara D., Larson, Richard A.
Publicado em 2009

Phase 2 Trial of the CDK4 inhibitor Palbociclib (PD0332991) at 125 mg dose in Well-Differentiated or Dedifferentiated Liposarcoma

Por Dickson, Mark A., Schwartz, Gary K., Keohan, Mary Louise, D’Angelo, Sandra P., Gounder, Mrinal M., Chi, Ping, Antonescu, Cristina R., Landa, Jonathan, Qin, Li-Xuan, Crago, Aimee M., Singer, Samuel, Koff, Andrew, Tap, William D.
Publicado no JAMA Oncol (2016)

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene...

Por Sutani, A, Nagai, Y, Udagawa, K, Uchida, Y, Koyama, N, Murayama, Y, Tanaka, T, Miyazawa, H, Nagata, M, Kanazawa, M, Hagiwara, K, Kobayashi, K
Publicado em 2006

A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3′- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer

Por Heath, Elisabeth I, Heilbrun, Lance K, Li, Jing, Vaishampayan, Ulka, Harper, Felicity, Pemberton, Pam, Sarkar, Fazlul H
Publicado em 2010

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Por O'Connor, Owen A., Horwitz, Steven, Masszi, Tamás, Van Hoof, Achiel, Brown, Peter, Doorduijn, Jeannette, Hess, Georg, Jurczak, Wojciech, Knoblauch, Poul, Chawla, Shanta, Bhat, Gajanan, Choi, Mi Rim, Walewski, Jan, Savage, Kerry, Foss, Francine, Allen, Lee F., Shustov, Andrei
Publicado no J Clin Oncol (2015)

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional...

Por Moreno, Carol, Montillo, Marco, Panayiotidis, Panayiotis, Dimou, Maria, Bloor, Adrian, Dupuis, Jehan, Schuh, Anna, Norin, Stefan, Geisler, Christian, Hillmen, Peter, Doubek, Michael, Trněný, Marek, Obrtlikova, Petra, Laurenti, Luca, Stilgenbauer, Stephan, Smolej, Lukas, Ghia, Paolo, Cymbalista, Florence, Jaeger, Ulrich, Stamatopoulos, Kostas, Stavroyianni, Niki, Carrington, Patrick, Zouabi, Hamadi, Leblond, Veronique, Gomez-Garcia, Juan C., Rubio, Martin, Marasca, Roberto, Musuraca, Gerardo, Rigacci, Luigi, Farina, Lucia, Paolini, Rossella, Pospisilova, Sarka, Kimby, Eva, Bradley, Colm, Montserrat, Emili
Publicado no Haematologica (2015)

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

Por Mascarenhas, John O., Talpaz, Moshe, Gupta, Vikas, Foltz, Lynda M., Savona, Michael R., Paquette, Ronald, Turner, A. Robert, Coughlin, Paul, Winton, Elliott, Burn, Timothy C., O’Neill, Peter, Clark, Jason, Hunter, Deborah, Assad, Albert, Hoffman, Ronald, Verstovsek, Srdan
Publicado no Haematologica (2017)

Short-term adaptation of the ruminal epithelium involves abrupt changes in sodium and short-chain fatty acid transport

Por Schurmann, Brittney L., Walpole, Matthew E., Górka, Pawel, Ching, John C. H., Loewen, Matthew E., Penner, Gregory B.
Publicado em 2014

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

Por Rangwala, Reshma, Leone, Robert, Chang, Yunyoung C, Fecher, Leslie A, Schuchter, Lynn M, Kramer, Amy, Tan, Kay-See, Heitjan, Daniel F, Rodgers, Glenda, Gallagher, Maryann, Piao, Shengfu, Troxel, Andrea B, Evans, Tracey L, DeMichele, Angela M, Nathanson, Katherine L, O’Dwyer, Peter J, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, Amaravadi, Ravi K
Publicado em 2014

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

Por Cortes, Jorge, Talpaz, Moshe, Smith, Hedy P., Snyder, David S., Khoury, Jean, Bhalla, Kapil N., Pinilla-Ibarz, Javier, Larson, Richard, Mitchell, David, Wise, Scott C., Rutkoski, Thomas J., Smith, Bryan D., Flynn, Daniel L., Kantarjian, Hagop M., Rosen, Oliver, Van Etten, Richard A.
Publicado no Haematologica (2017)

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

Por Gambacorti‐Passerini, Carlo, Orlov, Sergey, Zhang, Li, Braiteh, Fadi, Huang, Huiqiang, Esaki, Taito, Horibe, Keizo, Ahn, Jin‐Seok, Beck, Joseph T., Edenfield, William Jeffrey, Shi, Yuankai, Taylor, Matthew, Tamura, Kenji, Van Tine, Brian A., Wu, Shang‐Ju, Paolini, Jolanda, Selaru, Paulina, Kim, Tae Min
Publicado no Am J Hematol (2018)